Apollomics (APLM) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Apollomics (APLM) has outperformed Mereo BioPharma Group (MREO) over the past year, gaining 18.2% versus a loss of 80.9%. Apollomics is the larger company by market cap ($62.7 million vs $55.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | MREO |
|---|---|---|
| Share price | $21.50 | $0.3499 |
| Market cap | $62.67M | $55.88M |
| 1-day change | -0.92% | -6.74% |
| YTD return | +16.50% | -10.02% |
| 1-year return | +18.16% | -80.86% |
| 5-year return | — | -82.79% |
| EPS (TTM) | $-7.57 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.12 | $2.37 |
| 52-week low | $10.01 | $0.20 |
| Distance from 52-week high | -48.96% | -85.24% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +460.16% |
| Average volume | 21.69K | 4.04M |
| Shares outstanding | 2.91M | 159.69M |
| Employees | 14 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- APLM has outperformed MREO by 99.0 percentage points over the past year.
About Apollomics
APLM stock →Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
APLM vs MREO FAQ
Which is bigger, Apollomics or Mereo BioPharma Group?
Apollomics (APLM) is larger, with a market capitalization of $62.67M compared with $55.88M for Mereo BioPharma Group (MREO).
Which stock has performed better over the past year, APLM or MREO?
APLM returned +18.16% over the past 12 months, compared with -80.86% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and Mereo BioPharma Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.